<DOC>
	<DOCNO>NCT00039754</DOCNO>
	<brief_summary>Multiple myeloma disease reside primarily bone show sensitive radiation . Administration radiotherapy agent target bone , Holmium-166-DOTMP , conjunction melphalan autologous stem cell transplant , may improve patient 's chance responding treatment . The purpose study determine amount Holmium-166-DOTMP localize bone normal organ , evaluate safety efficacy Holmium-166-DOTMP treatment patient multiple myeloma .</brief_summary>
	<brief_title>A Trial Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP Patients With Multiple Myeloma</brief_title>
	<detailed_description>The purpose study estimate radiation absorb dose bone marrow kidney base whole-body gamma camera image data comparison obtain use mathematical model base whole body count small gamma detection device call thyroid probe ; obtain pharmacokinetic data follow administration 166Ho-DOTMP ; evaluate safety efficacy patient receive 25 Gy target therapy 166Ho-DOTMP 200 mg/m2 melphalan follow autologous peripheral blood stem cell transplant ( PBSCT ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Transplant</keyword>
	<keyword>Skeletal Targeted Radiotherapy</keyword>
	<keyword>Holmium</keyword>
</DOC>